t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs.
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
T
T
Narita
Department of Hematology and Oncology, Nagoya City West Medical Center, Nagoya, Japan.
A
A
Inagaki
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
T
T
Kobayashi
Department of Hematology and Oncology, Research Center for Radiation Casualty Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Y
Y
Kuroda
Department of Hematology and Immunology, Kanazawa Medical University, Uchinada, Japan.
T
T
Fukushima
Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
M
M
Nezu
Department of Hematology, Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
S
S
Fuchida
Division of Hematology and Oncology, Department of Internal Medicine, St Marianna University School of Medicine, Kanagawa, Japan.
H
H
Sakai
Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
N
N
Sekiguchi
Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan.
I
I
Sugiura
Department of Hematology and Oncology, Okayama University, Okayama, Japan.
Y
Y
Maeda
Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
H
H
Takamatsu
Oncology Center, Gunma University Hospital, Maebashi, Japan.
N
N
Tsukamoto
Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
D
D
Maruyama
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Y
Y
Kubota
Division of Hematology/Oncology, Department of Internal medicine, Tokai University School of Medicine, Isahara, Japan.
M
M
Kojima
Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
K
K
Sunami
Department of Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.
T
T
Ono
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
M
M
Ri
Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
K
0000000278593227
K
Tobinai
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
S
S
Iida
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019002:CD56 Antigen / Q000096:biosynthesis* / Q000235:genetics; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics*; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics*; D019938:Cyclin D1 / Q000096:biosynthesis / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009363:Neoplasm Proteins / Q000096:biosynthesis; D016019:Survival Analysis; D014178:Translocation, Genetic / Q000235:genetics; D016896:Treatment Outcome
C530104:CCND1 protein, human; D019002:CD56 Antigen; C522918:NCAM1 protein, human; D009363:Neoplasm Proteins; D019938:Cyclin D1